Last reviewed · How we verify
Live-attenuated CHIKV vaccine VLA1553
Live-attenuated CHIKV vaccine VLA1553 is a Vaccine Biologic drug developed by Valneva Austria GmbH. It is currently in Phase 2 development for Chikungunya.
Live-attenuated CHIKV vaccine targets the Chikungunya virus
Live-attenuated CHIKV vaccine targets the Chikungunya virus Used for Chikungunya.
At a glance
| Generic name | Live-attenuated CHIKV vaccine VLA1553 |
|---|---|
| Sponsor | Valneva Austria GmbH |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by introducing a weakened form of the Chikungunya virus to stimulate an immune response.
Approved indications
- Chikungunya
Common side effects
Key clinical trials
- VLA1553-403 Pregnancy Surveillance Study
- Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
- Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults (PHASE3)
- Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults (PHASE3)
- Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live-attenuated CHIKV vaccine VLA1553 CI brief — competitive landscape report
- Live-attenuated CHIKV vaccine VLA1553 updates RSS · CI watch RSS
- Valneva Austria GmbH portfolio CI
Frequently asked questions about Live-attenuated CHIKV vaccine VLA1553
What is Live-attenuated CHIKV vaccine VLA1553?
How does Live-attenuated CHIKV vaccine VLA1553 work?
What is Live-attenuated CHIKV vaccine VLA1553 used for?
Who makes Live-attenuated CHIKV vaccine VLA1553?
What drug class is Live-attenuated CHIKV vaccine VLA1553 in?
What development phase is Live-attenuated CHIKV vaccine VLA1553 in?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Valneva Austria GmbH — full pipeline
- Therapeutic area: All drugs in Vaccines
- Indication: Drugs for Chikungunya
- Compare: Live-attenuated CHIKV vaccine VLA1553 vs similar drugs
- Pricing: Live-attenuated CHIKV vaccine VLA1553 cost, discount & access